Research programme: marine anti-plaque compounds - Aphios
Alternative Names: Asterias; Marine anti-plaque compounds - AphiosLatest Information Update: 28 Apr 2023
At a glance
- Originator Aphios Corporation
- Developer Aphios Corporation; Massachusetts Institute of Technology; Scripps Institution of Oceanography
- Class Anti-inflammatories; Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Gingivitis
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Gingivitis in USA (PO, Paste)
- 07 Apr 2021 Preclinical development is still ongoing for Gingivitis in USA (Aphios Corporation website, April 2021)
- 07 Apr 2021 Aphios Corporation receives SBIR grant from National Institute of Dentistry and Craniofacial Research (NIDCR), National Institutes of Health for Asterias before April 2021 (Aphios Corporation website, April 2021)